Market Overview

Analysis: A CVS-Aetna Merger Would Be Revolutionary

Share:
Analysis: A CVS-Aetna Merger Would Be Revolutionary
Related CVS
3 Ways Amazon Could Transform Health Care
Trump Strikes At PBMs, Insurers, Drugmakers With Plans To Lower Consumer Prices
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update (Seeking Alpha)
Related AET
Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside
Lab Stocks: Baird Favors Laboratory Corp., Says Quest Diagnostics Is The Simple Choice
Tracking Larry Robbins' Glenview Capital Management Portfolio - Q1 2018 Update (Seeking Alpha)

Health care investors were blindsided on Thursday afternoon when Dow Jones reported that CVS Health Corp (NYSE: CVS) is exploring a $66 billion bid for Aetna Inc (NYSE: AET). As expected, Wall Street analysts have a lot to say about the potential deal.

In a new note on Friday, Citigroup analyst Alvin Concepcion said a marriage between CVS and Aetna makes sense in principle as the health care industry prepares for a major new competitor in Amazon.com, Inc. (NASDAQ: AMZN).

“In sum, we see this potential deal as both evolutionary and revolutionary given the dynamic healthcare environment and push toward consumerism coupled with a challenged retail backdrop and the need to combat a looming AMZN threat,” Concepcion said.

A $66 billion deal would be a tough pill for the $73 billion CVS to swallow.

At roughly $200 per share, Concepcion says the price for the potential deal is reasonable. That price represents 12.4x Aetna’a trailing 12-month EBITDA, which is within the range of the valuations of previous CVS acquisitions Caremark (11.8x) and Omnicare (22.0x).

However, Concepcion said CVS has a lot to gain from the potentially difficult deal. He estimates that the buyout could contribute an additional $0.24 in EPS for CVS within a year of completion. In addition, the two companies could leverage the power of their combined data to gain additional insights about customers.

Customers themselves could also be winners from the merger, benefitting from potentially lower pharmacy prices.

Citi has a Neutral rating and $87 price target for CVS stock.

Editor's note: On Dec. 1, Dow Jones reported CVS will acquire Aetna for $145 per share in cash, plus $62 in CVS stock.

Related Link: Walgreens: A Weak Stock Is A Weak Stock

Image Credit: By Ildar Sagdejev (Specious) - Own work, GFDL, via Wikimedia Commons

Latest Ratings for CVS

DateFirmActionFromTo
Apr 2018Bank of AmericaMaintainsBuyBuy
Feb 2018CitigroupMaintainsNeutralNeutral
Feb 2018Leerink SwannMaintainsOutperformOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Reiteration M&A Analyst Ratings General Best of Benzinga

 

Related Articles (AMZN + AET)

View Comments and Join the Discussion!